STMN1 (Ab-38) Antibody

What is STMN1 and what cellular functions does it regulate?

STMN1 (Stathmin 1) is a phosphoprotein that functions as a key regulator of microtubule dynamics. It prevents assembly and promotes disassembly of microtubules, thus playing a critical role in cytoskeletal reorganization . STMN1 is involved in the regulation of microtubule filament systems through its destabilizing effect on microtubules . Additionally, STMN1 has been implicated in neuronal development, with phosphorylation at Ser-16 potentially required for axon formation during neurogenesis . The protein also participates in the control of learned and innate fear responses, highlighting its importance in neurological function .

What are the validated applications for STMN1 (Ab-38) antibody?

The STMN1 (Ab-38) antibody has been validated for multiple experimental techniques including:

• Western Blot (WB): Successfully tested for detecting endogenous STMN1 in cell extracts from 293 and HeLa cells

• Immunohistochemistry (IHC): Validated for tissue section analysis

• Immunofluorescence (IF): Confirmed for cellular localization studies

• Enzyme-Linked Immunosorbent Assay (ELISA): Verified for quantitative protein detection

These applications have been validated across multiple species including human and rat samples, making this antibody versatile for comparative studies .

What epitope does the STMN1 (Ab-38) antibody recognize?

The STMN1 (Ab-38) antibody recognizes a specific epitope around amino acids 36-40 (P-L-S-P-P) of human Stathmin 1 . This antibody was generated by immunizing rabbits with a synthetic peptide corresponding to this sequence conjugated to KLH (Keyhole Limpet Hemocyanin) . The antibody is designed to detect endogenous levels of total Stathmin 1 protein rather than specific phosphorylated forms .

What are the optimal conditions for Western blotting with STMN1 (Ab-38) antibody?

For optimal Western blot results with STMN1 (Ab-38) antibody:

• Sample preparation: Extract proteins from cells using standard lysis buffers containing protease inhibitors

• Protein loading: 20-50 μg of total protein per lane is recommended

• Antibody dilution: Use at 1:500 to 1:1000 dilution (based on 1 mg/ml concentration)

• Blocking: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary antibody incubation: Overnight at 4°C

• Secondary antibody: Anti-rabbit IgG conjugated with HRP at 1:5000 dilution

• Detection: Enhanced chemiluminescence (ECL) system

The antibody has been successfully tested on 293 and HeLa cell extracts, showing specific bands at the expected molecular weight for STMN1 (approximately 19 kDa) .

How should STMN1 (Ab-38) antibody be stored and handled to maintain its efficacy?

For optimal storage and handling of STMN1 (Ab-38) antibody:

• Long-term storage: Keep at -20°C in aliquots to avoid repeated freeze-thaw cycles

• Short-term storage: May be kept at 4°C for periods of active use (up to 2 weeks)

• Formulation: The antibody is typically supplied in phosphate-buffered saline (pH 7.4) containing 150mM NaCl, 0.02% sodium azide, and 50% glycerol

• Avoid contamination: Use sterile technique when handling

• Thawing: Thaw aliquots on ice or at 4°C, and centrifuge briefly before use to collect solution at the bottom of the tube

• Working dilutions should be prepared fresh and used within 24 hours

How is STMN1 involved in cancer progression and metastasis?

Research has revealed complex relationships between STMN1 and cancer progression:

STMN1 expression is linked to metastatic behavior, with inhibition of STMN1 accelerating the metastatic process in some contexts . Interestingly, loss of STMN1 expression has been shown to activate p38 MAPK signaling, resulting in:

• Induction of EMT (Epithelial-Mesenchymal Transition), characterized by spindle-shaped cell morphology

• Increased expression of mesenchymal markers like vimentin

• Decreased expression of epithelial markers such as E-cadherin and ZO-1

• Upregulation of matrix metalloproteinases MMP-2 and MMP-9, enhancing extracellular matrix degradation and cell invasion

This paradoxical finding suggests that STMN1 may have context-dependent roles in cancer progression. In certain experimental systems, restoration of STMN1 expression promotes cell-cell adhesion and prevents pro-metastatic behavior, indicating its potential anti-metastatic function in some cancers .

What is the role of STMN1 in neurodegenerative diseases like SMA?

STMN1 has emerged as a potential disease modifier in motor neuron diseases, particularly Spinal Muscular Atrophy (SMA):

• STMN1 expression correlates with resistance to pathology in motor neurons, with vulnerable neurons showing significantly downregulated STMN1 levels

• AAV9-mediated delivery of STMN1 in SMA mouse models has demonstrated therapeutic effects:

  • Increased survival and weight gain

  • Improved motor function

  • Reduced neuromuscular junction (NMJ) pathology

  • Enhanced motor neuron preservation

Mechanistically, STMN1 therapy appears to improve SMA pathology by restoring microtubule networks and tubulin expression. In SMA models, α-tubulin levels are decreased in untreated spinal cords, but STMN1 treatment restores these levels to those of unaffected controls . This suggests STMN1's role in maintaining proper microtubule dynamics is critical for motor neuron health and function.

How does STMN1 interact with signaling pathways to regulate cell behavior?

STMN1 demonstrates complex interactions with multiple signaling pathways:

• p38 MAPK Pathway:

  • STMN1 is phosphorylated in response to p38 activation

  • p38 inhibitor SB203580 inhibits STMN1 activity

  • Paradoxically, loss of STMN1 results in increased p38 phosphorylation and activation

• TGF-β Signaling:

  • TGF-β1 treatment inhibits endogenous STMN1 expression

  • TGF-β can induce EMT through both p38-dependent and p38-independent mechanisms

  • STMN1 expression can be modulated by both TGF-β-dependent and TGF-β-independent activation of p38

• Ca²⁺/calmodulin-dependent Complexes:

  • A ternary complex formed by Ca²⁺/calmodulin-dependent protein kinase II (CaMK II), Siva1, and STMN1 results in STMN1 phosphorylation at Ser-16

  • This phosphorylation weakens STMN1-α-tubulin interactions and inhibits EMT and cell migration

These findings suggest that STMN1 functions at the intersection of multiple signaling networks, with its activity and expression levels being both regulated by and regulating these pathways.

What controls should be included when using STMN1 (Ab-38) antibody in experiments?

For rigorous experimental design with STMN1 (Ab-38) antibody, include the following controls:

• Positive controls:

  • Cell lines with known STMN1 expression (293 and HeLa cells have been validated)

  • Tissues with high STMN1 expression (brain tissue, particularly developing neurons)

• Negative controls:

  • Primary antibody omission to assess secondary antibody specificity

  • Isotype control (rabbit IgG) to detect non-specific binding

  • Blocking peptide competition assay using the immunizing peptide (aa 36-40) to confirm specificity

• Loading/technical controls:

  • Housekeeping proteins (β-actin, GAPDH) for Western blot normalization

  • Staining of nuclei (DAPI) for IF/IHC to assess tissue integrity

• Validation strategies:

  • siRNA knockdown of STMN1 to confirm antibody specificity

  • Comparison with other validated anti-STMN1 antibodies targeting different epitopes

How can researchers differentiate between total STMN1 and its phosphorylated forms?

Distinguishing between total and phosphorylated STMN1 is crucial for understanding its regulation:

• Antibody selection:

  • STMN1 (Ab-38) detects total STMN1 protein regardless of phosphorylation status

  • For phosphorylated forms, use phospho-specific antibodies targeting key sites (Ser16, Ser25, Ser38, and Ser63)

• Experimental approaches:

  • Western blot: Run parallel blots with total and phospho-specific antibodies

  • Phosphatase treatment: Treat one sample set with lambda phosphatase to remove phosphorylation and confirm phospho-specificity

  • 2D gel electrophoresis: To separate STMN1 based on phosphorylation-induced charge differences

• Data interpretation:

  • Calculate phosphorylation ratios (phospho-STMN1/total STMN1) to normalize for expression level differences

  • Consider the biological context, as phosphorylation at different sites affects STMN1 function differently

  • Remember that STMN1's activity in microtubule destabilization is inhibited by phosphorylation

What are common issues when using STMN1 (Ab-38) antibody in immunohistochemistry and how can they be resolved?

When performing immunohistochemistry with STMN1 (Ab-38) antibody, researchers may encounter these common challenges:

• High background staining:

  • Increase blocking time and concentration (try 5-10% serum from the species of the secondary antibody)

  • Optimize antibody dilution (try 1:100-1:500 range)

  • Include 0.1-0.3% Triton X-100 in washing steps

  • Use more stringent washing (increase number and duration of washes)

• Weak or no signal:

  • Optimize antigen retrieval methods (try heat-induced epitope retrieval in citrate buffer pH 6.0)

  • Decrease antibody dilution

  • Increase incubation time or temperature

  • Use signal amplification systems (avidin-biotin complex or tyramide signal amplification)

• Non-specific staining:

  • Pre-absorb primary antibody with the immunizing peptide

  • Use tissue from STMN1 knockout models as negative controls

  • Add 1-5% BSA to antibody diluent

• Inconsistent results between samples:

  • Standardize fixation protocols (duration and fixative type)

  • Control tissue thickness (use consistent section thickness, typically 5-10 μm)

  • Process all samples in parallel in the same experiment

How can researchers optimize the use of STMN1 (Ab-38) antibody for studying microtubule dynamics?

To effectively study microtubule dynamics using STMN1 (Ab-38) antibody:

• Co-localization studies:

  • Co-stain with anti-α-tubulin or anti-β-tubulin antibodies to visualize the relationship between STMN1 and microtubule networks

  • Use super-resolution microscopy techniques (STED, STORM) for detailed co-localization analysis

• Live-cell imaging:

  • Combine with GFP-tagged tubulin to monitor real-time effects of STMN1 manipulation on microtubule dynamics

  • Consider complementary techniques like FRAP (Fluorescence Recovery After Photobleaching) to assess microtubule turnover rates

• Experimental manipulations:

  • Compare acetylated α-tubulin levels (marker of stable microtubules) in normal and STMN1-manipulated samples as demonstrated in SMA studies

  • Use microtubule-stabilizing (taxol) or -destabilizing (nocodazole) agents as positive controls

  • Employ phospho-mimetic or phospho-resistant STMN1 mutants to understand how phosphorylation affects function

• Quantitative analysis:

  • Measure microtubule growth/shrinkage rates, catastrophe frequencies, and rescue events

  • Quantify the ratio of polymerized to free tubulin as a measure of STMN1 activity

  • Assess changes in microtubule orientation and organization using image analysis software

What emerging applications exist for STMN1 (Ab-38) antibody in therapeutic development?

Based on current research, several promising therapeutic applications involving STMN1 are emerging:

• Gene therapy for neurodegenerative diseases:

  • The success of scAAV9-STMN1 delivery in SMA mouse models suggests potential therapeutic applications for motor neuron diseases

  • Future research could explore optimal viral delivery methods, dosing regimens, and timing of intervention

  • Combination therapies with SMN-enhancing treatments could be investigated for synergistic effects

• Cancer treatment strategies:

  • Context-dependent roles of STMN1 in cancer progression suggest targeted approaches:

    • For cancers where STMN1 acts as an oncogene: Develop inhibitors of STMN1 function

    • For cancers where STMN1 loss promotes metastasis: Explore STMN1 replacement or stabilization strategies

  • STMN1 could serve as a biomarker for treatment response or metastatic potential

• Diagnostic applications:

  • Development of STMN1-based biomarker panels for cancer prognosis

  • Phospho-STMN1 signatures as predictors of disease-free survival in certain cancers

What are unresolved questions about STMN1's role in disease pathogenesis?

Several key questions remain unanswered regarding STMN1's role in disease:

• Mechanistic uncertainties:

  • How does STMN1 downregulation activate p38 MAPK signaling?

  • What determines whether STMN1 acts as a tumor promoter or suppressor in different cancer contexts?

  • How does STMN1 restoration improve motor neuron function without affecting SMN levels in SMA?

• Regulatory complexity:

  • What controls the tissue-specific expression patterns of STMN1?

  • How do different phosphorylation combinations (with four major phosphorylation sites) affect STMN1 function?

  • What is the role of STMN1 in non-dividing, post-mitotic cells such as neurons?

• Therapeutic potential:

  • Can STMN1-targeted therapies be effective across different neurodegenerative conditions?

  • Would systemic modulation of STMN1 have unintended consequences given its role in multiple cellular processes?

  • How might STMN1-based therapies interact with standard-of-care treatments for various diseases?